結(jié)核(TB)藥物耐藥是一個(gè)嚴(yán)重的公共健康問(wèn)題。一種新型多藥耐藥結(jié)核(MDR-TB)診斷檢測(cè)只需要2天就能夠提供檢測(cè)結(jié)果。

這種新型檢測(cè)比傳統(tǒng)的檢測(cè)方法更快的提供結(jié)果，傳統(tǒng)方法需要數(shù)周才能夠給出檢測(cè)結(jié)果。MDR-TB的分子學(xué)檢測(cè)十分迅速，但是技術(shù)更復(fù)雜而且價(jià)格昂貴。FastPlaque-Response是由創(chuàng)新新型檢測(cè)FIND(Geneva, Switzerland)基金研制開(kāi)發(fā)的，這是由Bill和Melinda Gates與Biotec Laboratories(Ipswich, UK)創(chuàng)建的。該檢測(cè)已經(jīng)在歐洲注冊(cè)正在接受FIND的評(píng)估，以用于TB高流行的國(guó)家。

Rapid Test Detects Multi-Drug-Resistant TB
 
Tuberculosis (TB) drug resistance is a major public health problem. A new diagnostic test for multi-drug-resistant TB (MDR-TB) provides results in only two days.

The new test is much faster than conventional methods that take weeks to yield results. Molecular tests for MDR-TB are also rapid but are much more technically complicated and expensive. The FastPlaque-Response was developed by the Foundation for Innovative New Diagnostics FIND (Geneva, Switzerland), which is a Bill and Melinda Gates initiative, and Biotec Laboratories Ltd. (Ipswich, UK). The test has been registered in Europe and is in the process of being evaluated by FIND for use within the public health sector of countries where there is a high incidence of TB.